Introduction {#s1}
============

Several behavioral, physiological, and neurochemical adaptations taking place following bilateral olfactory bulbectomy (OBX) in rats can be found in patients with major depressive disorder ([@CIT0019]; [@CIT0040]). These effects of OBX include hyperactivity to mild stress ([@CIT0002]; [@CIT0022]), cognitive impairment ([@CIT0047]; [@CIT0049]), circadian rhythm and sleep disruptions ([@CIT0025]), perturbations of eating habits ([@CIT0030]), and enhanced levels of corticosteroids ([@CIT0006]; [@CIT0019]).

The most replicated behavioral characteristic of this model is the increase in locomotor activity seen, in the open field, following olfactory bulb ablation ([@CIT0046]; [@CIT0008]; [@CIT0005]). It is also well established that chronic but not acute administration of various drugs, such as the selective serotonin (5-HT) reuptake inhibitors (SSRIs) fluoxetine ([@CIT0029]), paroxetine ([@CIT0008]), and escitalopram (for review, see [@CIT0040]; [@CIT0004]), can reverse behavioral hyperactivity observed in OBX rats in the open field. Furthermore, in the latter study, reversal of hyperactivity was no longer present 10 weeks after cessation of drug administration ([@CIT0004]).

Removal of the olfactory bulbs in rats also results in alterations of 5-HT, norepinephrine (NE), and dopamine (DA) systems ([@CIT0042]; [@CIT0028]; [@CIT0039]; [@CIT0040]). Particularly, changes in 5-HT synthesis rate, 5-HT levels, 5-HT transporters (5-HTTs), and 5-HT receptor densities are reported in different brain structures following OBX ([@CIT0050]; [@CIT0048]; [@CIT0018]; [@CIT0045]; [@CIT0035]; [@CIT0037]).

Preclinical studies show that antidepressant treatments increase 5-HT neurotransmission with a time course that is consistent with their delayed therapeutic effect. This enhancement would, however, be mediated through different mechanisms. Whereas bupropion increases discharge frequency of 5-HT neurons after 2 and 14 days of administration in naïve rats ([@CIT0013]; [@CIT0014]), SSRIs, including paroxetine, decrease 5-HT neuronal activity after 2 days of administration that recovers to the control level only after 2 to 3 weeks of administration (Pin[@CIT0033]; [@CIT0009]; [@CIT0012]). Hence, long-term administration of SSRIs increases 5-HT levels in the projecting area following recovery of firing of 5-HT neurons to control level and desensitization of the terminal 5-HT~1B~ autoreceptor (Pin[@CIT0033]). An increase of 5-HT transmission was also obtained by short- and long-term administration of bupropion but also in a time-dependent fashion ([@CIT0014], [@CIT0015]). In contrast, sustained bupropion administration (2 days) increases the firing activity of 5-HT neurons above normal, partly because it desensitizes the 5-HT~1A~ autoreceptor through an indirect noradrenergic mechanism. In addition, prolonged administration (14 days) of bupropion desensitizes the α~2~-adrenergic heteroreceptors on 5-HT terminals ([@CIT0015]), thereby delineating their primary site of action on the NE system.

The aim of this study was to determine how 2 antidepressant drugs with different mechanisms of action, the SSRIs paroxetine and bupropion, act on in vivo characteristics of the 5-HT system in an OBX rat model, where several 5-HT alterations have taken place. The choice of these 2 antidepressant drugs stemmed mainly from their different mechanism of action on 5-HT neurons.

Methods {#s2}
=======

Animals {#s3}
-------

The in vivo electrophysiological experiments were carried out in male Sprague-Dawley rats (Charles River, St. Constant, QC, Canada) weighing between 300 and 500g at the time of recordings. Upon arrival, the rats were allowed to acclimatize to their new environment for 1 week prior to start of any drug administration or experiment. The animals were kept, 2 per cage, under standard laboratory conditions (12:12-hour--light/--dark cycle with access to food and water ad libitum). Following surgery, control and OBX rats were kept individually in cages. All the experiments were approved by the local Animal Care Committee (Institute of Mental Health Research) and conducted in accordance with the Canadian Council on Animal Care) for the care and use of laboratory animals.

OBX Surgery {#s4}
-----------

Bilateral OBX was performed in rats anesthetised with equitezine ([@CIT0027]). For olfactory bulb ablation, rats were mounted in a stereotaxic frame. A medline incision was made extending at least 1mm to bregma. A burr hole was drilled at 7mm anterior to bregma and 2.5mm either side of the midline at a point corresponding to the posterior margin of the orbit of the eye. After a localized electrical coagulation of the dura and sagittal sinus, olfactory bulbs were removed by suction with a vacuum pump attached to a Pasteur pipette. The burr hole was filled with haemostatic sponges and the wound was closed with sterile sutures. Sham-operated rats were treated similarly, with the exception that olfactory bulbs were not removed. After surgery, animals were injected 5mL intraperitoneally (i.p.) with 5% glucose and temgesic for postsurgical analgesia. The animals were allowed to recover for 14 days following surgery, at which time behavioral changes occur ([@CIT0024]). On the 14th to 18th days following surgery, the rats were recorded or implanted with minipumps for drug administration. Only rats that showed complete ablation of the olfactory bulbs and no damage to the frontal cortex were included for data analysis.

Assessment of Hyperlocomotion in OBX Rats {#s5}
-----------------------------------------

The open field chamber consisted of a square plastic box (85×85×70cm). Since conditions of very high brightness are crucial to observe the hyperactivity in OBX rats ([@CIT0026]; [@CIT0040]), the inner faces of the walls were covered with aluminium foil and illumination was provided by a 100-watt bulb. Each rat was placed into the center of the open field, and exploratory activity was monitored by a video camera fixed above the arena and relayed to a computer system that calculates the walked distance during the first 5 minutes (Viewpoint Life Sciences, Lyon, France). All experiments were performed between 8:30 and 10:30 [am]{.smallcaps}.

Minipump Implantation and Electrophysiological Experiments {#s6}
----------------------------------------------------------

The rats were anesthetized with isoflurane to implant, subcutaneously, the osmotic Alzet minipumps (Alza, Palo Alto, CA) to ensure slow and steady release of bupropion (30mg/kg/d; [@CIT0011]), paroxetine (10mg/kg/d; [@CIT0003]), or vehicle (water for bupropion, 50% water+50% ethanol for paroxetine) for 2, 14, and 28 days. The electrophysiological experiments were carried out with the minipump in place. Prior to the electrophysiological recordings, rats were anesthetized with chloral hydrate (400mg/kg, i.p.) and mounted in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA). Supplemental doses of the anesthetic (100mg/kg, i.p.) were given to maintain constant anesthesia and prevent any nociceptive reaction to pinching of the hind paws. Body temperature was maintained at 37°C throughout the experiment with a heating pad. Prior to the electrophysiological experiments, a catheter was inserted in a lateral tail vein for systemic intravenous injection of pharmacological agents.

Electrophysiological Recordings of Dorsal Raphe Nucleus (DRN) 5-HT Neurons {#s7}
--------------------------------------------------------------------------

In vivo extracellular recordings of presumptive 5-HT neurons were obtained using single-barrel glass micropipettes. The impedance of the electrodes was between 4 and 6 MΩ. The microelectrodes were positioned 0.9 to 1.2mm anterior to lambda on the midline and lowered into the DRN. The 5-HT neurons were encountered over a distance of 1mm starting immediately below the ventral border of the Sylvius aqueduct. These neurons were identified by their slow (0.5--2.5 Hz), regular firing rate and a long duration (0.8--1.2ms) positive action potential ([@CIT0044]).

Electrophysiological Recordings of Locus Coeruleus NE Neurons {#s8}
-------------------------------------------------------------

NE neurons were reliably recorded at the following coordinates (in millimeters from lambda): anterior-posterior (AP), -1.0 to -1.2; median-lateral (ML), 1.0 to 1.3; dorsal-ventral (DV), 5.0 to 7.0. They were identified by their regular firing rate (1--5 Hz) and their positive action-potential duration, which is between 0.8 and 1.2 milliseconds. They can also be identified by a brief neuronal excitation to a nociceptive pinch of the contralateral hind paw followed by a short period of inhibition (see [@CIT0041]).

Electrophysiological Recordings of Ventral Tegmental Area (VTA) DA Neurons {#s9}
--------------------------------------------------------------------------

DA neurons were reliably recorded at the following coordinates (in millimeters from lambda): AP, 3.2 to 3.6; ML, 0.9 to 1.1; DV, 7.0 to 9.0. They were identified by their established electrophysiological criteria ([@CIT0043]), including: (1) spontaneous firing rate between 2 and 90 spikes/s, exhibiting bursting activity or irregular firing; (2) biphasic or triphasic waveforms, with an initial positive deflection (usually notched followed by prominent negative phase; (3) long duration potential (2--4 milliseconds); and (4) low pitch sound when monitored by an audioamplifier. A duration \>1.1 milliseconds from the start of the action potential to the center of the negative trough was also used to determine the DA neuron identity ([@CIT0043]).

Bursts Analysis {#s10}
---------------

The firing patterns of the monoaminergic neurons were analyzed by interspike interval (ISI) burst analysis. The onset of a burst was signified by the occurrence of 2 spikes with ISI \<0.08 seconds for NE and DA and ISI \<0.01 seconds for 5-HT. The termination of a burst was defined as an ISI \>0.16 seconds for NE and DA and ISI \>0.01 seconds for 5-HT ([@CIT0016]; [@CIT0017]; [@CIT0010]).

Extracellular Recording and Microiontophoresis of Dorsal Hippocampus CA3 Pyramidal Neurons {#s11}
------------------------------------------------------------------------------------------

Extracellular recording and microiontophoresis of CA3 pyramidal neurons were performed with 5-barreled glass micropipettes. The impedance of the electrodes ranged from 2 to 4 MΩ. The central barrel used for the unitary recording was filled with a 2-M NaCl solution, and the 4 side barrels were filled with the following solutions: 5-HT creatinine sulfate (10mM in 200mM NaCl, pH 4), quisqualic acid (1.5mM in 200mM NaCl, pH 8), and a 2-M NaCl solution used for automatic current balancing. The electrodes were lowered into the dorsal CA3 region of the hippocampus using the following coordinates: 4mm anterior to lambda and 4.2mm lateral. Pyramidal neurons were encountered at a depth of 4.0±0.5mm below the surface of the brain. Because these neurons do not spontaneously discharge in chloral hydrate anesthetized rats, they were activated within their physiological firing range (10--15 Hz; [@CIT0020]) by a small current of quisqualate in nanoamperes (nAs; using Harvard Apparatus module, Montreal, Canada). The CA3 pyramidal neurons were identified by their large amplitude (0.5--1.2 mV) and long-duration simple action potentials, alternating with complex spike discharges.

5-HT~1A~ Receptor Sensitivity {#s12}
-----------------------------

Neuronal responsiveness of the CA3 pyramidal neurons after 5-HT~1A~ receptors activation was determined by microiontophoretically applying 5-HT (in nA) for 50 seconds and measuring the number of spikes suppressed per nA. The more spikes are suppressed per nA, the more sensitive are the receptors.

Determination of 5-HT Reuptake Inhibition {#s13}
-----------------------------------------

To determine the degree to which the 5-HTTs were blocked by paroxetine, the 50% recovery time (RT50) was measured by determining the time (in seconds) following a 50-second ejection period of 5-HT to recover 50% of the initial firing rate (Pin[@CIT0032]).

Statistics {#s14}
----------

The data are presented as mean values ± SEM. Statistical comparisons were performed using the Mann-Whitney U test or Wilcoxon signed rank test when a parameter was studied in control and treated rats. For DRN experiments, statistical comparisons were carried out using a 1-way analysis of variance (ANOVA) on ranks followed by Dunn's method for all pairwise multiple comparison procedures. For the tonic activation, statistical comparisons were carried out using a 2-way analysis of variance with repeated measures (treatment as the main factor) followed by the Tukey posthoc analysis. Statistical significance was taken as *P*\<.05.

Drugs {#s15}
-----

Bupropion and paroxetine (Sequoia Research Products, Pangbourne, UK). WAY 100635, 5-HT creatinine sulfate, and chloral hydrate were purchased from Sigma (St. Louis, MO). Quisqualic acid was purchased from Tocris (Ellisville, MO).

Results {#s16}
=======

Open Field {#s17}
----------

Following ablation of their olfactory bulbs, rats were significantly more active compared with shams in the open field (total distance traveled: prebulbectomy, 1357±222cm \[12 rats\], postbulbectomy: 2809±406cm \[12 rats\]; *P*\<.01; Mann-Whitney U test). Rats tested in the behavioral paradigm were not used for electrophysiology experiments.

DRN 5-HT Neurons Activity in OBX Rats {#s18}
-------------------------------------

Sham rats from different treatment groups were pooled together, because there was no significant difference in their 5-HT neuron firing activity. Fourteen to 18 days following OBX, the average firing rate of 5-HT neurons was significantly decreased by 36% compared with control ([Figure 1](#F1){ref-type="fig"}; *P*\<.001, 1-way ANOVA). However, the average firing activity returned to control levels 4 weeks after the olfactory ablation ([Figure 1](#F1){ref-type="fig"}; *P*\>.05, 1-way ANOVA).

![Mean (±SEM) of the firing rate of dorsal raphe nucleus (DRN) serotonin (5-HT) neurons in control and olfactory bulbectomy (OBX) rats that received vehicle, paroxetine (10mg/kg/d) or bupropion (30mg/kg/d), for 2, 14, and 28 days. The number at the bottom indicates the total number of neurons recorded in each group. \*\**P*\<.01 and \**P*\<.05.](ijnppy_pyu050_f0001){#F1}

The mean number of neurons found per track was not changed in OBX rats compared with controls (control group: 4±0.2, N=17 rats; OBX group: 4.4±0.5, N=9 rats; *P*\>.05; Mann-Whitney U test).

Locus Coeruleus NE Neurons Activity in OBX Rats {#s19}
-----------------------------------------------

OBX resulted in no change in the neuronal firing rate of NE neurons. However, although the number of neurons displaying burst activities was increased (22% in control \[90 neurons in 5 rats\] vs 42% in OBX rats \[115 neurons in 7 rats\], Mann-Whitney U, *P*=.003), the percentage of spikes in bursts was not changed (control: 5±1 \[20 neurons\]; OBX: 7±0.9 \[48 neurons\], *t* test, *P*\>.05).

VTA DA Neurons Activity in OBX Rats {#s20}
-----------------------------------

There was no change in firing rate of VTA DA neurons following olfactory bulb ablation (sham: 5±0.2 Hz, 56 neurons in 5 rats; OBX: 5±0.3 Hz, 64 neurons in 6 rats). Moreover, there was no change in bursting activity of VTA DA neurons (percentage of spikes in bursts, control: 29±3 \[in 5 rats\]; OBX: 34±4 \[in 6 rats\]).

Effect of Paroxetine and Bupropion on the Firing Activity of 5-HT Neurons in OBX Rats {#s21}
-------------------------------------------------------------------------------------

Because the firing activity of NE and DA neurons was largely unaffected by OBX, the effects of 2 antidepressants with distinct mechanisms of action were examined only on the 5-HT system.

After 14 to 18 days following OBX, rats were administered either bupropion (30mg/kg/d) or paroxetine (10mg/kg/d) for short and long periods. Two days of bupropion administration to OBX rats resulted in recovery to normal of the dampened firing activity of 5-HT neurons compared with OBX rats receiving vehicle ([Figure 1](#F1){ref-type="fig"}; P \< .01, 1-way ANOVA). Following a 14-day administration of bupropion, the firing rate of 5-HT neurons in OBX rats remained at control levels ([Figure 1](#F1){ref-type="fig"}).

In OBX rats administered with paroxetine for 2, 14, and 28 days, the discharge activity of 5-HT neurons remained significantly inhibited by 58%, 58%, and 42%, respectively, compared with rats treated with vehicle ([Figure 1](#F1){ref-type="fig"}; *P* \< .01, 1-way ANOVA). The inhibition of 5-HT neurons firing seen in OBX rats that received paroxetine (for 2 and 14 days) was reversed to control discharge level after the injection of 100 µg of the selective 5-HT~1A~ receptor antagonist WAY 100635 (control group: 1.2±0.1 Hz; 2-day treated group: 1.1±0.1 \[23 neurons in 2 rats\]; 14-day treated group: 1.1±0.1 \[39 neurons in 2 rats\]).

Effect of Bupropion and Paroxetine on the 5-HT Elements in the Hippocampus of OBX Rats {#s22}
--------------------------------------------------------------------------------------

For all CA3 pyramidal neurons, iontophoretic application of 5-HT induced an inhibition of their firing activity ([Figure 2](#F2){ref-type="fig"}). To determine the sensitivity of the 5-HT~1A~ receptors located on pyramidal neurons, the number of action potentials suppressed by 5-HT ejection (nA) was calculated. Short- and long-term administration of bupropion did not modify the suppressant effect of 5-HT on firing activity of CA3 pyramidal neurons. The mean number of spikes suppressed per nA was not significantly different in OBX rats administered paroxetine and bupropion for 14 days compared with OBX rats treated with vehicle (spikes suppressed per nA; vehicle group: 8±1 \[n=7\]; paroxetine group: 9±1 \[n=8\] and 7±1 \[n=6\] in the bupropion group; *P*\>.05; 1-way ANOVA).

![Integrated firing rate histograms of dorsal hippocampus CA3 pyramidal neurons showing their responsiveness to the microiontophoretic application of serotonin (5-HT) and intravenous injection of WAY 100635 in vehicle-treated rats (A) and a rat administered with either paroxetine (B; 10mg/kg/d) or bupropion (C; 30mg/kg/d). Note the increase in firing activity of pyramidal neurons after the injection of WAY 100635. (D) Degree (percentage ± SEM) of increase of the firing activity of pyramidal neurons in control rats and those treated with paroxetine and bupropion for 14 days after the administration of WAY 100635. \* *P*\<.05, \*\**P*\<.01.](ijnppy_pyu050_f0002){#F2}

It is established that 5-HT reuptake blockers increase RT50 values (Pin[@CIT0032]). Indeed, the mean RT50 value was significantly increased in OBX rats administered with paroxetine for 14 days (RT50; paroxetine group: 89±15 s \[n=8\] compared with vehicle group 24±2 s \[n=7\]; *P*\<.001; Mann-Whitney U test).

As an indication that iontophoretic application of 5-HT was exerting its inhibitory effect via 5-HT~1A~ receptors, the latter action was nearly abolished by WAY 100635 administration ([Figure 2](#F2){ref-type="fig"}; *P* \< .05, Wilcoxon signed-rank test).

Should there be a significant tonic activation of the 5-HT~1A~ receptors, their blockade will result in significant enhancement of the firing activity of pyramidal neurons. In OBX rats that received vehicle, the overall effect of WAY 100635 was not significant on the firing activity of CA3 pyramidal neurons ([Figure 2A](#F2){ref-type="fig"}, [D](#F2){ref-type="fig"}). However, after 2 weeks administration of paroxetine, although the overall effect was not statistically significant, the tonic activation of 5-HT~1A~ receptors was significantly increased when the dose of WAY 100635 reached 100 µg/kg (*P*\<.05). However, in rats that received bupropion for 2 weeks, blockade of 5-HT~1A~ receptors induced a significant enhancement in the mean firing activity of pyramidal neurons starting at 50 µg/kg ([Figure 2](#F2){ref-type="fig"}; *P* \< .001, F(2, 81) = 8.7, 2-way ANOVA for repeated measures, followed by Tukey post hoc test; vehicle group: *n* = 8, paroxetine group: *n* = 8, bupropion group: *n* = 6). This shows that the effectiveness of bupropion on tonic activation of 5-HT~1A~ receptors is higher than bupropion in this model.

Discussion {#s23}
==========

An increase in locomotor activity in a novel environment such as the open field has been reported in many studies following olfactory bulb removal ([@CIT0040]; [@CIT0045]). It is noteworthy that this alteration seen after ablation was reported not to be due to anosmia proper, as peripherally anosmic rats do perform as sham rats in the open field paradigm ([@CIT0046]; [@CIT0006]; for review, see [@CIT0040]). In keeping with these previous findings ([@CIT0008]; [@CIT0040]; [@CIT0024]; [@CIT0005]), OBX rats in the present study showed a significant increase in locomotion in the open field. Interestingly, the hyperactivity phenomenon was reported to be a durable characteristic of the OBX rats, as it is still present 20 weeks after surgery ([@CIT0045]). It has also been reported to be reversed by chronic but not acute administration with several antidepressants, including SSRIs ([@CIT0007], [@CIT0008]; [@CIT0040]).

The present study showed that the firing activity of DRN 5-HT neurons was significantly decreased 2 weeks after OBX. Because the firing activity of NE and DA neurons was unchanged, as shown in the present study, these results cannot be explained by a diminution of the excitatory effect of NE and DA neurons through an action on α~1~-adrenoceptors and D~2~ receptors, respectively ([@CIT0021]).

This decrease in firing of 5-HT neurons was unlikely to have been due to an overactivation of 5-HT~1A~ autoreceptors, which would not have been possible in the presence of a significant decrease in 5-HT synthesis and a probable diminution of 5-HT concentrations in dorsal and medial raphe nuclei of OBX-rats ([@CIT0001]; [@CIT0048]; [@CIT0018]). Even though the mechanism underlying this decrease in firing is not clear, data point to an alteration in 5-HT elements of DRN. Indeed, [@CIT0035] reported a significant decrease in tryptophan hydroxylase-positive cells in the rat DRN following OBX. However, in the present study, although 5-HT neurons firing was decreased, no reduction in the number of neurons encountered per electrode trajectory was observed, suggesting no change at least in the number of presumptive 5-HT neurons recorded in DRN of OBX rats. Consistently with the present results, it was reported that there was no general loss of neuronal function, because there was a similar increase in 5-HT accumulation following tryptophan loading in OBX rats compared with controls ([@CIT0045]).

Unlike behavioral adaptations that lasted weeks after OBX, the diminished firing rate of 5-HT in OBX rats at 14-day postsurgery recovered to control levels after 28 days. It is worth noting that previous studies have shown that some adaptations, such as hyperactivity, found in OBX rats are durable whereas others are reversible. Indeed, although it was shown that the hyperactivity seen in OBX-rats lasted for 5 months postbulbectomy ([@CIT0045]), at least one study showed, for instance, that brain reward function, as measured by intra-cranial self-stimulation, was deficient for 8 days after OBX before returning to baseline levels ([@CIT0038]). The exact mechanisms underlying the presence or absence of such adaptations are unclear and need to be examined in future studies.

Despite recovery of the activity of 5-HT neurons after 1 month of ablation, it remained inhibited following paroxetine administration for 14 and 28 days, at which time neurons usually return to control levels in naïve rats under the same regimen ([@CIT0003]). It is possible that the lack of recovery of 5-HT neurons firing stems from the inability of paroxetine to increase 5-HT levels in DRN, which consequently would have resulted in 5-HT~1A~ autoreceptor desensitization, allowing a return to the control level of the firing. Indeed, 14-day administration of the SSRI citalopram in OBX rats did not reverse the decrease of DRN 5-HT synthesis and release ([@CIT0001]; [@CIT0018]). The lack of increase in 5-HT cannot be explained by an augmentation in 5-HTT density in OBX rats as was previously postulated, since there was no change in 5-HTT density in the DRN of these rats ([@CIT0037]).

In the hippocampus, even though the density of 5-HT~1A~ receptors was increased in OBX rats ([@CIT0036]), this did not result in an enhancement of the responsiveness of these receptors after 14-day paroxetine administration ([Figure 2](#F2){ref-type="fig"}). This indicates that 5-HT~1A~ receptors remained normosensitive in the hippocampus, similarly to naïve rats that received the same regimen ([@CIT0003]). However, an increase in the tonic activation of the 5-HT~1A~ receptors was shown here, although only following injection of a high dose of WAY 100635 (100 μg/kg) in paroxetine-treated OBX rats but to a lesser extent than that obtained in naïve rats that received this SSRI ([@CIT0003]). Accordingly, a dampened enhancement of extracellular levels of 5-HT in the hippocampus was already reported, since local application of the SSRI fluvoxamine significantly increased extracellular 5-HT in this region and to a greater extent in sham than OBX rats ([@CIT0048]; [@CIT0018]; [@CIT0045]; [@CIT0034]). It is not clear if the increase in 5-HTT density in OBX rat hippocampus is the cause for this dampening in 5-HT levels, as was proposed, since conflicting results were reported (no change vs an increase; [@CIT0050]; [@CIT0023]; [@CIT0037]). Furthermore, 5-HTT blockade as measured by the RT50 (a direct measure of 5-HTT reuptake; Pin[@CIT0032]) was shown in the current work to be increased to the same degree in paroxetine-treated OBX rats than in naïve rats ([@CIT0003]). Altogether, these results showed that in the hippocampus of OBX rats, paroxetine induced a relatively modest increase in tonic activation of 5-HT~1A~ receptor, 5-HT synthesis ([@CIT0018]), and 5-HT release ([@CIT0045]) compared with bupropion. It is worth noting, however, that paroxetine attenuated OBX-induced hyperactivity ([@CIT0007], [@CIT0008]).

An enhancement of tonic activation of the 5-HT~1A~ receptors was obtained in the hippocampus of OBX rats following a 14-day regimen with bupropion using smaller doses of WAY 100635 than those used to induce it in rats that received paroxetine ([Figure 2](#F2){ref-type="fig"}). This increase is similar to that obtained from previous studies using bupropion in naïve rats ([@CIT0015]). Altogether, these results indicate that inasmuch as 5-HT~1A~ receptor sensitivity did not change following bupropion regimen, an increase was observed in its net effect of bupropion administration on 5-HT neurotransmission in OBX rats that was comparable with that obtained in naïve rats ([@CIT0015]). This increase likely resulted from attenuated function of α~2~-adrenoceptors located on 5-HT terminals ([@CIT0015]) combined with normalized firing of 5-HT neurons after 14-day administration of bupropion, as reported here. However, the fact that 5-HT neuron firing was not higher in OBX rats that received bupropion than that in naïve rats ([@CIT0013]; [@CIT0014]) may stem from the fact that basal firing of 5-HT neurons was much lower in OBX rats compared with naïve animals.

Clinically, it is well known that certain patients with major depressive disorder may respond to some classes of antidepressants but not to others. The biological basis for this remains elusive. The present results showed that 5-HT transmission was not enhanced to the same degree using a SSRI in rats with a presynaptic anomaly of 5-HT neurons (ie, a diminished firing activity) than in rats receiving bupropion, an antidepressant with primary sites of action on catecholamine systems, which appeared to be largely unaltered in this model. The therapeutic implications of these findings are that patients with olfactory bulb atrophy may have a preferential response to bupropion than to a SSRI. Indeed, in patients with major depressive disorder, there is a correlation between the severity of depressive symptoms and atrophy of the olfactory bulbs ([@CIT0031]). It would thus be interesting to examine the antidepressant response using the 2 drugs studied herein in a clinical setting in relation to bulb atrophy.
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